Growth hormone deficiency and vascular risk

Clinical Endocrinology

Volumn 57, Issue 1, 2002, Pages 11-24

  McCallum, Roland W ^a   Petrie, John R ^a   Dominiczak, Anna F ^a   Connell, John M C ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; GROWTH HORMONE; NITRIC OXIDE;

BLOOD PRESSURE; BLOOD VESSEL WALL; BODY BUILD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIUM; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HYPOPHYSIS DISEASE; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MORBIDITY; MORPHOLOGY; MORTALITY; PRIORITY JOURNAL; PULSE WAVE; REVIEW; VASODILATATION;

ADULT; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; GREAT BRITAIN; HEMOSTASIS; HUMAN GROWTH HORMONE; HUMANS; HYPERTENSION; PITUITARY DISEASES; PREVALENCE; RISK; SOMATOSTATIN; VASCULAR RESISTANCE;

EID: 0036064285     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01559.x     Document Type: Review

References (153)

1. Plasma homocysteine is not a major risk factor for vascular disease in growth hormone deficient adults
2. Coronary risk in growth hormone deficient hypopituitary adults: Increased predicted risk is due largely to lipid profile abnormalities
3. Blood pressure circadian rhythms in adult growth hormone deficiency following growth hormone replacement
4. Comparison between insulin-induced hypoglycaemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults
5. Usefulness of IGF-1 assay for the diagnosis of GH deficiency in adults
6. Growth hormone and hepatic lipoprotein metabolism
7. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase
8. Control of lipolysis and its relevance to development of obesity in man
9. Adult growth hormone-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment
10. Low density lipoprotein subclass patterns and risk of myocardial infarction
11. The effect of growth hormone on glucose metabolism and insulin secretion in man
12. Life expectancy following surgery for pituitary tumours
13. The effect of hypopituitarism on life expectancy
14. Endothelial dysfunction: Implications for therapy of cardiovascular diseases
15. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
16. Therapeutic controversy: Treatment of growth hormone deficiency in adults
17. Measuring forearm blood flow and interpreting the responses to drugs and mediators
18. Metabolic abnormalities in growth hormone deficient adults. II. Carbohydrate tolerance and lipid metabolism
19. The effects of short and long term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance
20. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition
21. Metabolic implications of body fat distribution
22. Soluble L-selectin in atherosclerosis: Relationship to soluble E-selectin and soluble P-selectin
23. Clinical aspects of growth hormone deficiency in adults
24. Serum lipid levels in growth hormone deficient men
25. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations
26. Nitric oxide may mediate the haemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study
27. The incidence of cerebrovascular accidents in patients with pituitary adenoma
28. Biosynthetic growth hormone changes the collagen and elastin contents and biomechanical properties of the rat aorta
29. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival and tumor recurrence
30. Increased cerebrovascular mortality in patients with hypopituitarism
31. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors
32. Cardiovascular and renal effects of growth hormone
33. The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency
34. Abnormal vascular reactivity in growth hormone deficiency
35. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency
36. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
37. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults
38. Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity
39. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: A double-blind placebo-controlled study
40. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy
41. Endothelial cell in physiology and in the pathophysiology of vascular disorders
42. Impaired cardiac performance in growth hormone deficient adults and its improvement after growth hormone replacement
43. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels
44. Noninvasive pulse wave analysis for the early detection of vascular disease
45. Recombinant human insulin-like growth factor-I increases forearm blood flow
46. An evaluation of methods for imaging and quantifying coronary and carotid lumen stenosis and atherosclerosis
47. The growth hormone deficiency syndrome in adults
48. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength
49. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: Stimulation of the renin-aldosterone system
50. Glucose clamp technique: A method for quantifying insulin secretion and resistance
51. Clinical review. Treatment of obesity: Need to focus on high risk abdominally obese patients
52. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism
53. Growth hormone treatment of growth hormone deficient adults results in a marked increase in Lp(a) and HDL-cholesterol concentrations
54. Is sympathetic neural hyperactivity in chronic heart failure affected by heart transplantation?
55. Is vascular mortality increased in hypopituitarism?
56. Cardiovascular mortality among pituitary insufficient patients
57. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
58. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency
59. Elevated plasma homocysteine levels are associated with enhanced oxidative stress and endothelial dysfunction in adult hypopituitary patients with growth hormone deficiency
60. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency
61. Peripheral glucose metabolism in human hyperprolactinaemia
62. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency
63. Effect of growth hormone, prolactin and insulin on the release of IL-1 alpha, IFN-gamma and IL-4 by staphylococcal enterotoxin A-stimulated splenocytes
64. The pituitary gland
65. An open 36-month study of lipid changes with growth hormone in adults: Lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency
66. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: Evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity
67. Carotid intima-media thickness: Correlation with the British Regional Heart Study risk score
68. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects
69. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients
70. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices
71. Inhibitory effect of growth hormone on TNF-alpha secretion and nuclear factor-kappa B translocation in lipopolysaccharide stimulated human monocytes
72. Influence of fibroblast growth factor (bFGF) and insulin-like growth factor (IGF-1) on cytoskeletal and contractile structures and on atrial natriuretic factor (ANF) expression in adult rat ventricular cardiomyocytes in culture
73. Hypertension and cardiac hypertrophy in growth hormone-deficient rats
74. Insulin and insulin-like growth factor-1 cause coronary vasorelaxation in vitro
75. Nitric oxide synthesis inhibitor prevents vasodilatation by insulin-like growth factor I
76. Stable d-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat
77. Effects of human growth hormone in man
78. Insulin resistance in growth-hormone deficient adults: Defects in glucose utilisation and glycogen synthase activity
79. Growth hormone deficiency and cardiovascular risk
80. Diagnosis of growth hormone deficiency in adults
81. Cushing's syndrome
82. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans
83. Insulin-like growth factor 1 stimulates lipid oxidation, reduced protein oxidation, and enhances insulin sensitivity in humans
84. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro
85. Growth hormone-deficient adults are insulin-resistant
86. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults
87. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults
88. Hormonal and metabolic rhythms in Cushing's syndrome
89. Role of lipids and lipoprotein fractions in assessing atherogenesis. The Framingham Study
90. Nitric oxide: An endogenous modulator of leukocyte adhesion
91. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement
92. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents
93. HDL-cholesterol reduction associated with adult growth hormone replacement
94. Aortic compliance measurements using Doppler ultrasound: In vivo biochemical correlates
95. Aortic distensibility in growth hormone deficient adults
96. Endocrine function in patients with pituitary adenoma before and after hypophysectomy
97. Prevalence of diabetes and impaired glucose tolerance in adult hypopituitarism on low dose oral hydrocortison replacement therapy
98. A comparative study of six lipoprotein(a) assays in seventeen laboratories within the British Isles
99. Can normalization of vascular cytoadhesive activity be explained by the anti-atherosclerosis effect of growth hormone?
100. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary patients
101. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary patients
102. Endothelial function in hypertension: The role of superoxide anion
103. Predictive value of waist-to-hip ratio on cardiovascular risk events
104. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes
105. Long-term effects of growth hormone (GH) on body fluid distribution in GH deficient adults: A four months double blind placebo controlled trial
106. Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: Possible involvement of renin and atrial natriuretic factor
107. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man
108. Growth hormone deficiency and replacement in elderly hypopituitary adults
109. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency
110. Low density lipoprotein particle size in hypopituitary adults on conventional hormone replacement therapy
111. The effect of 3 months of recombinant growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: A minimal model analysis
112. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 Years of follow-up of the participants in the study of men born in 1913
113. Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy
114. IGF-1 increases forearm blood flow without increasing forearm glucose uptake
115. Growth hormone (GH) and atherosclerosis: Changes in morphology and function of major arteries during GH treatment
116. The natural history of Cushing's syndrome
117. Linking lipoprotein(a) and coronary heart disease
118. Role of insulin resistance in human disease
119. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain
120. Mechanisms of free fatty acid-induced insulin resistance in humans
121. Premature mortality due to cardiovascular disease in hypopituitarism
122. Cardiovascular risk factors in adult patients with growth hormone deficiency
123. Altered lipid pattern explains increased cardiovascular mortality in hypopituitary patients with growth hormone deficiency
124. The pathogenesis of atherosclerosis: A perspective for the 1990s
125. Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in the hypophysectomised rat
126. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors
127. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal 7alpha-hydroxylase in the rat
128. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients
129. Growth hormone and the heart
130. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
131. Ultrasound B-mode imaging in observational studies of atherosclerosis progression
132. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study). Socioeconomic impact and health status
133. Effects of growth hormone (GH) administration on homocyst(e)ine levels in man with GH deficiency: A randomized controlled trial
134. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: A randomized, controlled clinical trial
135. Growth hormone replacement in adults
136. Effects of growth hormone on endothelial function in growth hormone deficient (GHD) adults: A randomised placebo-controlled study
137. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: The effect of growth hormone replacement and a comparison with control subjects
138. Analogy between endothelial/mesangial cell and endothelial/vascular smooth muscle cell interactions: Role of growth factors and mechanotransduction
139. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology
140. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency
141. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes
142. Editorial. Growth hormone and cardiovascular disease: An area in rapid growth
143. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
144. Association between premature mortality and hypopituitarism
145. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients
146. Direct demonstration of insulin-like growth factor 1-induced nitric oxide production by endothelial cells
147. Insulin-like growth factor I diminishesin vivoand in vitro vascular contractility: Role of vascular endothelium
148. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults
149. Sexual dimorphism in 11β hydroxysteroid dehydrogenase activity and its relation to fat distribution and insulin sensitivity; a study in hypopituitary subjects
150. Physiological growth hormone secretion in adult growth hormone deficiency: Comparison with normal controls
151. Fibrinogen as a risk factor for stroke and myocardial infarction
152. Endothelial-dependent vascular effects of insulin and insulin-like growth factor 1 in the perfused rat mesenteric artery and aortic ring